P0579: Predictive Modeling for Colectomy Risk in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis: A Brazilian Multicentric Study Utilizing Machine Learning.ECCO'25Year: 2025
Authors: da Silva, B.C.(1)*;Kronbauer, A.H.(2);Chebli, J.M.F.(3);Chebli, L.A.(3);Ferreira, S.D.C.(4);Lima, G.A.S.(5);Rzetelna, H.(6);Freire, C.C.F.(7);Braga, L.L.B.C.(8);Santana, G.O.(9);Parente, J.M.L.(10);
(1)Hospital da Bahia, Gastroenterology, Salvador Bahia, Brazil;(2)Universidade Salvador / Unifacs, Computer Science, Salvador, Brazil;(3)Hospital Universitário da Universidade Federal de Juiz de Fora, Gastroenterology, Juiz de Fora, Brazil;(4)Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - SP, Gastroenterology, Ribeirão Preto, Brazil;(5)Hospital das Clínicas da Universidade Federal de Pernambuco, Gastroenterology, Recife, Brazil;(6)Hospital Geral da Santa Casa da Misericórdia do Rio de Janeiro, Gastroenterology, Rio de Janeiro, Brazil;(7)Hospital Geral Cesar Cals, Gastroenterology, Fortaleza, Brazil;(8)Universidade Federal do Ceará, Gastroenterology, Fortaleza, Brazil;(9)State University of Bahia, School of Medicine, Salvador, Brazil;(10)Universidade Federal do Piauí, Gastroenterology, Teresina, Brazil;
Kim YS, Hurley EH, Park Y, Ko S. Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease. Intest Res. 2023 Sep 1. doi:10.5217/ir.2023.00039. Epub ahead of print. PMID: 37519211.
Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023 Jul;55(7):1380-7. doi:10.1038/s12276-023-01042-9. PMID: 37464092; PMCID: PMC10394020.
Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022 Jan;23(1):40-55.
P0580: Efficacy and safety results of tulisokibart re-induction treatment in participants with ulcerative colitis in the Phase 2 ARTEMIS-UC clinical trialECCO'25Year: 2025
Authors: HoquePhD, S.S.(1)*;Sands, B.E.(2);Feagan, B.G.(3,4);Yen, M.(5);Dong, B.(5);Zhou, W.(5);Danese, S.(6,7);
(1)Whipps Cross University Hospital, Department of Gastroenterology, London, United Kingdom;(2)Icahn School of Medicine at Mount Sinai- New York- New York., Dr. Henry D. Janowitz Division of Gastroenterology, New York City, United States;(3)University of Western Ontario, Division of Gastroenterology- Department of Medicine, London, Canada;(4)Alimentiv, Gastroenterology, London, Canada;(5)Merck & Co.- Inc., Clinical Research, Rahway, United States;(6)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(7)University Vita-Salute San Raffaele, Gastroenterology, Milano, Italy;
1. Sands et al. N Engl J Med 2024; 26;391(12):1119-1129
P0582: Do we need a Structured Transition Programme for patients with IBD? The Irish ExperienceECCO'25Year: 2025
Authors: Doherty, J.(1,2);Hurley, C.(3)*;Girod, P.(4);Peacock, J.(5);Stallard, L.(2);Quinn, S.(2);Broderick, A.(2);Stenke, E.(2);Hussey, S.(2);Hartery, K.(1);Kevans, D.(1);O Donnell, S.(6);Slattery, E.(5);Cullen, G.(4);Doherty, G.(7);Murphy, C.(3);Bourke, B.(2);Dunne, C.(1);
(1)St James Hospital, Department of Gastroenterology, Dublin, Ireland;(2)Children's Health Ireland- Crumlin Hospital, Department of Gastroenterology, Dublin, Ireland;(3)Cork University Hospital, Department of Gastroenterology, Cork, Ireland;(4)St Vincent's University Hospital, Department of Gastroenterology, Dublin, Ireland;(5)University College Hospital Galway, Department of Gastroenterology, Galway, Ireland;(6)Tallaght University Hospital- Tallaght, Department of Gastroenterology, Dublin, Ireland;(7)INITIative IBD Research Network, www.initiativeibd.ie, Dublin, Ireland;
1. Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, et al. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut [Internet]. 2017;66(6):988–1000. Available from: http://dx.doi.org/10.1136/gutjnl-2016-313000
P0583: The Effects of a Dual-Strain Probiotic Versus Placebo on Cytokine Levels in Patients with Ulcerative ColitisECCO'25Year: 2025
Authors: Carroll, A.(1)*;Meagher, S.(1);Walker, C.(1);Magdeldin, H.(1);McNamara, D.(1);Ryan, B.(1);O'Donnell, S.(1);Breslin, N.(1);Corr, S.(2);O'Connor, A.(1);
(1)Tallaght University Hospital, Gastroenterology, Dublin, Ireland;(2)Trinity College Dublin, Microbiology, Dublin, Ireland;
1. Römkens TEH, van Vugt-van Pinxteren MWJ, Nagengast FM, van Oijen MGH, de Jong DJ. High prevalence of fatigue in inflammatory bowel disease: A case control study. Journal of Crohn's and Colitis. 2011;5(4):332-7.
2. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012 Nov 3;380(9853):1606-19.
P0584: Rituximab versus infliximab for the treatment of PR3-ANCA Positive Moderately to Severely Active Ulcerative Colotis: A retrospective Multicentre Real-World StudyECCO'25Year: 2025
Authors: Yu, Q.(1)*;Yiyu, C.(1);Yidong, C.(1);Zhu, L.(1);
(1)Union Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of Gastroenterology, Wuhan, China;
1.Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflammatory intestinal diseases. May 2021;6(2):117-122. doi:10.1159/000515361
2.Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflammatory bowel diseases. Feb 2007;13(2):123-8. doi:10.1002/ibd.20054
3.Jürgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. The American journal of gastroenterology. Aug 2010;105(8):1811-9. doi:10.1038/ajg.2010.95
P0585: A treat to target approach in IBD: contemporary real-world perspectives from an international surveyECCO'25Year: 2025
Authors: Sharip, M.T.(1)*;Brezina, B.(1);La Revilla Negro, J.(1);Subramanian, S.(1);Parkes, M.(1);Raine, T.(1);Noor, N.M.(1);
(1)Cambridge University Hospital NHS Trust, Gastroenterology, Cambridge, United Kingdom;
P0586: Nationwide population-based cohort study on the use and persistence of infliximab (IV and SC) in France: the Riposte IBD studyECCO'25Year: 2025
Authors: Kirchgesner, J.(1)*;Quiles, N.(2);Foulley, L.(3);Habauzit, C.(3);Benkhalifa, S.(3);Prati, C.(4);
(1)AP-HP- Hôpital Saint-Antoine, Gastroenterology, Paris, France;(2)Hôpital Saint-Joseph, Dermatology, Marseille, France;(3)Celltrion Healthcare France, Medical, Issy Les Moulineaux, France;(4)CHRU Besançon, Rheumatology, Besançon, France;
P0587: Effectiveness and safety of Risankizumab in Crohn’s disease patients from a large Italian cohort: preliminary results from the RESOLVE IgIBD studyECCO'25Year: 2025
Authors: Scaldaferri, F.(1);Di Vincenzo, F.(2)*;Allocca, M.(3);Aloi, M.(4);Balestrieri, P.(5);Bertani, L.(6);Bezzio, C.(7);Bodini, C.(8);Calabrese, E.(9);Caprioli, F.(10);Cicala, M.(11);Danese, S.(12);Del Zanna, E.(13);Fantini, M.C.(14);Festa, S.(15);Fiorino, G.(16);Furfaro, F.(17);Gabbiadini, R.(18);Geccherle, A.(19);Laterza, L.(20);Marzo, M.(21);Mastronardi, M.(22);Mocci, G.(23);Monterubbianesi, R.(24);Onali, S.(25);Onidi, F.M.(23);Pica, R.(26);Principi, M.(27);Pugliese, D.(28);Savarino, E.(29);Tursi, A.(30);Variola, A.(31);Armuzzi, A.(32);
(1)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, IBD Unit- CeMAD Translational Research Laboratories- Digestive Disease Center CeMAD- Dipartimento di Scienze Mediche e Chirurgiche- Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;(2)Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy;(3)- IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Department of Gastroenterology and Endoscopy, Milano, Italy;(4)Sapienza University, Department of Pediatrics- Pediatric Gastroenterology and Liver Unit, Roma, Italy;(5)Fondazione Policlinico Universitario Campus Bio-Medico and Università Campus Bio-Medico di Roma, Gastroenterology Unit, Roma, Italy;(6)University Hospital of Pisa, IBD Unit- Department of General Surgery and Gastroenterology, Pisa, Italy;(7)Humanitas University- Pieve Emanuele, IBD Center- IRCCS Humanitas Research Hospital- Rozzano- MI- Italy- Department of Biomedical Sciences, Rozzano, Italy;(8)University of Genoa, Gastroenterology Unit- Department of Internal Medicine, Genova, Italy;(9)University of Rome Tor Vergata, Gastrointestinal Unit- Departement of Systems Medicine, Roma, Italy;(10)Università degli Studi di Milano- Milano - Italy Gastroenterology and Endoscopy Unit- Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Department of Pathophysiology and Transplantation, Milano, Italy;(11)Fondazione Policlinico Universitario Campus Bio-Medico, Operative Research Unit of Gastroenterology, Operative Research Unit of Gastroenterology, Italy;(12)IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milano, Italy;(13)Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Department of Pathophysiology and Transplantation, Milano, Italy;(14)University of Cagliari- Cagliari - Italy Azienda Ospedaliero-Universitaria AOU di Cagliari, Department of Medical Science and Public Health, Cagliari, Italy;(15)Ospedale S. Filippo Neri, IBD Unit, Roma, Italy;(16)San Camillo-Forlanini Hospital, IBD Unit, Roma, Italy;(17)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy Unit, Milano, Italy;(18)IRCCS Humanitas Research Hospital, IBD Center- Department of Gastroenterology, Rozzano, Italy;(19)IRCCS Ospedale Sacro Cuore Don Calabria- Negrar di Valpolicella, IBD Unit, Verona, Italy;(20)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, IBD Unit- Digestive Disease center CeMAD- Department of Medical and Surgical Sciences, Roma, Italy;(21)"Veris-Delli Ponti" Hospital, Division of Gastroenterology, Scorrano, Italy;(22)"IRCCS S. De Bellis"- Castellana Grotte, Unità operativa semplice - IBD, Castellana Grotte, Italy;(23)"Brotzu" Hospital, Division of Gastroenterology, Cagliari, Italy;(24)A.O. "S. Camillo-Folanini", Division of Gastroenterology, Roma, Italy;(25)Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy;(26)"S. Pertini" Hospital, Division of Gastroenterology- IBD Unit, Roma, Italy;(27)AOU Policlinico, Emergency and Organ Transplantation Department- Section of Gastroenterology, Bari, Italy;(28)Ospedale Isola Tiberina- Gemelli isola, Dipartimento di Emergenza e Medicina Interna, Roma, Italy;(29)University of Padua, Department of Surgery- Oncology and Gastroenterology- Department of Medical and Surgical Specialties, Padova, Italy;(30)Territorial Gastroenterology Service, ASL BAT- Andria, Andria, Italy;(31)IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar, Italy;(32)IRCCS Humanitas Research Hospital- Rozzano, IBD Center- Department of Biomedical Sciences, Rozzano, Italy;
P0588: Efficacy and health-related quality of life associated with second-line vedolizumab after one prior first-line anti-tumour necrosis factor treatment in patients with active ulcerative colitis: A meta-analysis of the GEMINI-1 and VISIBLE-1 trialsECCO'25Year: 2025
Authors: Atreya, R.(1)*;Kirchgesner, J.(2);Cheah, Z.(3);Biedermann, P.(4);Bakker, L.(5);Meyer, M.(6);Raine, T.(7);
(1)University Hospital Erlangen- Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine, Erlangen, Germany;(2)AP-HP- Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(3)OPEN Health HEOR and Market Access, Modelling & Meta-analysis, London, United Kingdom;(4)Takeda Pharmaceuticals International AG, Medical Affairs- Europe & Canada, Zurich, Switzerland;(5)OPEN Health HEOR & Market Access, Modelling & Meta-analysis, Rotterdam, Netherlands Antilles;(6)Takeda Pharma AG, Medical Affairs, Zurich, Switzerland;(7)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;
1. Feagan BG et al.N Engl J Med 2013;369:699-710.
2. Sandborn WJ et al.Gastroenterology 2020;158:562-572 e12.
3. Sandborn W. J. et al. Crohns Colitis 360 2023;6:otad076.
P0589: High treatment persistence following infliximab dose escalation in Inflammatory Bowel Disease: A real world studyECCO'25Year: 2025
Authors: Salehi, O.(1)*;Gondal, F.(1);Terlato, M.(1);Pillay, L.(1);Segal, J.P.(1);
(1)Royal Melbourne Hospital, Gastroenterology, Parkville, Australia;
1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541-1549.2. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1233-1238.
P0590: Long term outcomes of biologic therapy for the treatment of prepouch ileitis: a multi-centre multi-national retrospective studyECCO'25Year: 2025
Authors: Ghersin, I.(1)*;Calini, G.(2);Koifman, E.(3);Segal, J.(4);Argyriou, O.(5);McLaughlin, S.(6);Johnson, H.(6);Rottoli, M.(2);Sahnan, K.(5);Warusavitarne, J.(5);Hart, A.(1);
(1)St. Mark's National Bowel Hospital & Academic Institute, Department of Gastroenterology, London, United Kingdom;(2)IRCCS Azienda Ospedaliero-Universitaria di Bologna, Surgery of the Alimentary Tract, Bologna, Italy;(3)Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel;(4)Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(5)St. Mark's National Bowel Hospital & Academic Institute, Department of Colorectal Surgery, London, United Kingdom;(6)The Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom;
P0591: Janus Kinase Inhibitors Improve Liver Biochemistry in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: an ECCO CONFER Study.ECCO'25Year: 2025
Authors: Soriano, A.(1)*;Maggi , D.(2);Kagramanova, A.(3);Molnar, T.(4);Halasz, R.(4);Desmedt, V.(5);Holvoet, T.(5);Savarino, E.V.(6);Barberio, B.(6);Juillerat, P.(7);Vieujean, S.(8);Zelinkova, Z.(9);Durikova, D.(10);Kubíčková, K.(10);Avni Biron, I.(11);Aratari , A.(2);Bezzio, C.(12);Bettenworth, D.(13);Clifford, C.(14);Desideri, F.(15);Felice, C.(16);Levartovsky, A.(17);Melotti, L.(18);Pugliese, D.(19);Scaldaferri, F.(20);Viganò, C.(21);Schnoy, E.(22);Teich, N.(23);Shouval, D.(24);Drobne, D.(25);
(1)IBD Unit, Department of Internal Medicine - Gastroenterology Division- Santa Maria Nuova Hospital- IRCCS, Reggio Emilia, Italy;(2)IBD Unit, San Filippo Neri Hospital, Rome, Italy;(3)Moscow Clinical Scientific Centre, IBD Department, Moscow, Russian Federation;(4)Center for Gastroenterology- University of Szeged, Department of Internal Medicine, Szeged, Hungary;(5)IBD Unit, University Hospital of Ghent, Ghent, Belgium;(6)Gastroenterology Unit, Department of Surgery- Oncology and Gastroenterology – DiSCOG University of Padua – Azienda Ospedaliera di Padova, Padova, Italy;(7)Crohn's and Colitis Center- Fribourg, University of Bern, Fribourg, Switzerland;(8)CHU Liege, Service de gastro-entérologie- hépatologie et oncologie digestive, Sart Tilman, Belgium;(9)Nemocnica Bory - Penta Hospitals, Department of Gastroenterology, Bratislava, Slovakia;(10)IBD clinical and research centre, Iscare Clinic, Prague, Czech Republic;(11)IBD Unit, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel;(12)IBD Unit, Department of Gastroenterology- IRCCS Humanitas, Milan, Italy;(13)IBD Unit, University of Munster, Munster, Germany;(14)IBD Unit, St Vincent's University Hospital Dublin, Dublin, Ireland;(15)IBD Unit, Bolzano Central Hospital, Bolzano, Italy;(16)University of Padova, Department of Medicine DIMED, Padova, Italy;(17)IBD Unit, Gastroenterology- Sheba Medical Center- Tel-Hashomer- Israel, Tel Aviv, Israel;(18)IBD Unit, Internal Medicine Sant'Orsola-Bologna Hospital, Bologna, Italy;(19)IBD Unit, Dipartimento di Medicina e Chirurgia Traslazionale- Catholic University of Rome, Rome, Italy;(20)IBD Unit, CEMAD- Policlinico A. Gemelli- Catholic University of Rome, Rome, Italy;(21)Gastroenterology Unit, Fondazione IRCCS San Gerardo dei Tintori Monza- Milano Bicocca University, Milan, Italy;(22)IBD Unit, University Hospital Augsburg, Augsburg, Germany;(23)Internal Medicine and Digestive Diseases, Leipzig University, Leipzig, Germany;(24)Institute of Gastroenterology- Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel;(25)University Medical Center of Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;
Schregel I, Ramos GP, Ioannou S, Culver E, Färkkilä M, Schramm C; International PSC Study Group. Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study. Clin Gastroenterol Hepatol. 2023;21(13):3448-3450.e3. doi: 10.1016/j.cgh.2023.01.014.
Khrom M, Long M, Dube S, Robbins L, Botwin GJ, Yang S, Mengesha E, Li D, Naito T, Bonthala NN, Ha C, Melmed G, Rabizadeh S, Syal G, Vasiliauskas E, Ziring D, Brant SR, Cho J, Duerr RH, Rioux J, Schumm P, Silverberg M, Ananthakrishnan AN, Faubion WA, Jabri B, Lira SA, Newberry RD, Sandler RS, Xavier RJ, Kugathasan S, Hercules D, Targan SR, RB Sartor, Haritunians T, McGovern DPB. Comprehensive association analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease. Gastroenterology. 2024;167(2):315-332. doi: 10.1053/j.gastro.2024.02.026.
Dold L, Kalthoff S, Frank L, Zhou T, Esser P, Lutz P, Strassburg CP, Spengler U, Langhans B. STAT Activation in Regulatory CD4 (+) T Cells of Patients with Primary Sclerosis Cholangitis. Immune Inflamm Dis. 2024;12(4):e1248. doi: 10.1002/iid3.1248.
P0592: Safety of the Adjuvant Recombinant Herpes Zoster Vaccine in Crohn’s Disease and Ulcerative Colitis: A Real-World StudyECCO'25Year: 2025
Authors: Kim, D.H.(1)*;Park, Y.H.(2);Kang, S.B.(3);Kim, K.O.(4);Park, S.H.(5);Lee, Y.J.(6);Lee, J.(7);Moon, W.(8);Park, S.J.(9);Na, S.Y.(10);Kim, E.S.(11);Oh , S.J.(12);Shin, S.Y.(13);
(1)Chonnam National University Hospital, Division of gastroenterology- Department of Internal medicine and Inflammatory Bowel disease Clinic, Gwnagju, Korea- Republic Of;(2)Ewha Womans University College of Medicine, Department of Internal Medicine, Seoul, Korea- Republic Of;(3)Daejeon St. Mary’s Hospital, Department of Internal Medicine- College of Medicine, Daejeon, Korea- Republic Of;(4)Yeungnam University College of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(5)Asan Medical Center- University of Ulsan College of Medicine, Department of Gastroenterology, Seoul, Korea- Republic Of;(6)Keimyung University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(7)College of Medicine- Chosun University, Department of Internal Medicine, Gwangju, Korea- Republic Of;(8)Kosin University College of Medicine, Department of Internal Medicine, Busan, Korea- Republic Of;(9)Severance Hospital, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;(10)Incheon St. Mary's Hospital, Department of Internal Medicine, Incheon, Korea- Republic Of;(11)Korea University College of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Seoul, Korea- Republic Of;(12)Kyung Hee University Hospital- Kyung Hee University College of Medicine, Department of Gastroenterology- Center for Crohn's and Colitis, Seoul, Korea- Republic Of;(13)Chung-Ang University College of Medicine, Department of Internal Medicine, Seoul, Korea- Republic Of; IBD research group of KASID (Korean Association for the Study of Intestinal Diseases)
1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640.
2. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med 2013;369:255-263.3. Marra F, Parhar K, Huang B, Vadlamudi N. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis 2020;7:ofaa005.
4. Imafuku S, Dormal G, Got
Y, Jégou C, Rosillon D, Matsuki T. Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. J Dermatol 2020;47:236-244.
5. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1483-1490.
6. Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res 2023;21:88-99.
7. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37.
8. Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis 2021;224:S429-s442.
9. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010;51:197-213.
10. James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine. Ann Pharmacother 2018;52:673-680.
11. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349.
12. Khan N, Patel D, Trivedi C, et al. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2018;16:1919-1927.e1913.
13. Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection 2014;42:325-334.
14. Yun H, Yang S, Chen L, et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol 2016;68:2328-2337.
15. Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci 2014;29:1706-1710.
P0593: High-dose Tofacitinib in Acute Severe Ulcerative Colitis: an option to avoid colectomy?ECCO'25Year: 2025
Authors: Sierra Ausín, M.(1)*;Latras Cortés, I.(1);Suárez Álvarez, P.(1);Cano Sanz, N.(1);Elosua González, T.(2);
(1)Complejo Asistencial Universitario de León, IBD Unit. Gastroenterology, León, Spain;(2)Complejo Asistencial Universitario de León, Surgery, León, Spain;
1.Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol. 2021 Oct;19(10):2112-2120.e1. doi: 10.1016/j.cgh.2021.05.038. Epub 2021 May 25. PMID: 34048936; PMCID: PMC8760630.
P0594: Efficacy and safety of etrasimod in Japanese UC patients: results of a phase 2 dose-ranging studyECCO'25Year: 2025
Authors: Takeuchi, K.(1);Nakase, H.(2);Hisamatsu, T.(3);Matsuoka, K.(4)*;Arai, S.(5);Yuasa, H.(6);Oe, M.(6);Ono, R.(6);Keating, M.(7);Gu, G.(8);Lazin, K.(9);McDonnell, A.(10);Fokuta, K.(5);Hibi, T.(11);
(1)Tsujinaka Hospital Kashiwanoha, Department of Gastroenterology- IBD Center, Chiba, Japan;(2)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Hokkaido, Japan;(3)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(4)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Chiba, Japan;(5)., Pfizer Japan Inc, Tokyo, Japan;(6)., Pfizer R&D Japan, Tokyo, Japan;(7)., Pfizer Inc, New York- NY, United States;(8)., Pfizer Inc, La Jolla- CA, United States;(9)., Pfizer AG, Zürich, Switzerland;(10)., Pfizer Ltd, Sandwich, United Kingdom;(11)Kitasato University- Kitasato Institute Hospital, Center for Advanced Inflammatory Bowel Disease Research and Treatment, Tokyo, Japan;
1. Sandborn WJ et al. Gastroenterology 2020; 158: 550–561.
Pfizer’s generative artificial intelligence tool MAIA was used to assist production of the abstract first draft. Authors reviewed/edited and take responsibility for the content.
P0595: Comparative effectiveness between ustekinumab and vedolizumab after anti-TNF failure in Ulcerative Colitis: Real-world experienceECCO'25Year: 2025
Authors: Jairath, R.(1)*;Zoughlami, A.(1);Mahmoud, O.(2);Pilote, N.(3);Solitano, V.(4,5);Mohammad, D.(6);Afif, W.(1);Bitton, A.(1);Wild, G.(1);Lakatos, P.L.(1);Narula, N.(7);Jairath, V.(4);Bessissow, T.(1);
(1)McGill University Health Centre, Department of Gastroenterology, Montreal, Canada;(2)McGill University Health Centre, Deparment of Internal Medicine, Montreal, Canada;(3)McGill University Health Centre, McGill University - Faculty of Medicine, Montreal, Canada;(4)London Health Sciences Centre- Western University, Division of Gastroenterology, London, Canada;(5)IRCCS Ospedale San Raffaele- University Vita-Salute San Raffaele, Division of Gastroenterology and Gastrointestinal Endoscopy, Milan, Italy;(6)Farncombe Family Digestive Health Research Institute- McMaster University, Division of Gastroenterology, Hamilton, Canada;(7)Hamilton Health Sciences- McMaster University, Division of Gastroenterology, Hamilton, Canada;
1. Holvoet T, Truyens M, De Galan C, et al. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. J Clin Med. 2024;13(2). doi:10.3390/JCM13020365
2. Nomura K, Shibuya T, Odakura R, et al. Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study. Biomedicines. 2024;12(9):1991. doi:10.3390/BIOMEDICINES12091991
3. Fumery M, Serrero M, Bouguen G, et al. Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent. J Crohns Colitis. 2024;18(10):1615-1621. doi:10.1093/ECCO-JCC/JJAE063
4. Meyer A, Fumery M, Peyrin-Biroulet L, et al. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scand J Gastroenterol. 2022;57(12):1454-1462. doi:10.1080/00365521.2022.2095668
P0596: Fecal bile acids predict the therapeutic effect of biological agents in patients with ulcerative colitisECCO'25Year: 2025
Authors: Guo, J.(1);Yuan, X.(1);Li, C.(1)*;Zhang, X.(1);
(1)The second hospital of Hebei medical university, Gastroenterology, Shijiazhuang, China;
[1] Li N, Zhan S, Tian Z, et al. Alterations in bile acid metabolism associated with inflammatory bowel disease. Inflamm Bowel Dis, 2021, 27(9): 1525-1540.
[2] Ding NS, McDonald J, Perdones-Montero A, et al. Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease. J Crohns Colitis, 2020, 14(8): 1090-1102.
[3] Lee J, Plichta D, Hogstrom L, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe, 2021, 29(8): 1294-1304.e4.2.
P0597: Clinical and biochemical correlates of infliximab pharmacokinetics in adult patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Pool, I.A.(1);Volkerink, I.(2);Stavast, M.(2);Kosterink, J.G.W.(2);Dijkstra, G.(1);Mian, P.(2);Bourgonje, A.R.(1,3)*;
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Clinical Pharmacy and Pharmacology, Groningen, The Netherlands;(3)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, The Netherlands;
1. Hemperly, A & Vande Casteele, N. Clin Pharmacokinet. 2018 doi: 10.1007/s40262-017-0627-0.
P0598: Feasibility and limitations in adopting treat-to-target approach in inflammatory bowel diseases (IBD): real-life scenarioECCO'25Year: 2025
Authors: Harindranath, S.(1)*;Desai, D.C.(1);Mehta, N.(1);Abraham, P.(1);Gupta, T.(1);Dhoble, P.(1);Mehendale, S.(1);
(1)PD Hinduja Hospital and Research centre, Department of gastroenterology, Mumbai, India;
1. Bryant RV, Costello SP, Schoeman S, et al. Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. J Gastroenterol Hepatol. 2018;33:599-6072.
2. Selinger C, Carbonell J, Kane J, Omer M, Ford AC. Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission. Frontline Gastroenterol. 2020;12: 30-38
3. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets In Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160: 1570–8.
P0599: Efficacy and safety of intravenous methylprednisolone and hydrocortisone in Acute Severe Ulcerative Colitis (ASUC) – a posthoc analysis of the IASO trialECCO'25Year: 2025
Authors: Thakor, A.(1)*;Drobne , D.(2);Vaja, S.(3);Subramanian, S.(1);Qian, W.(3);Davis-Wilkie, C.(3);Parkes, M.(1);Kaser, A.(1);Raine, T.(1);
(1)Cambridge University Hospitals NHS Foundation Trust, Gastroenterology, Cambridge, United Kingdom;(2)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(3)Cambridge University Hospitals NHS Foundation Trust, Cambridge Clinical Trials Unit, Cambridge, United Kingdom;
1. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106.
2. Wiles A , Bredin F , Chukualim B , et al. In the treatment of flares of inflammatory bowel disease, intravenous hydrocortisone causes greater falls in blood potassium and more severe episodes of hypokalaemia than methylprednisolone. Gut 2011;60(Suppl 1):A223–4.doi:10.1136/gut.2011.239301.471
